Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

Researchers in France have developed an antibody that blocks AMH, reversing PCOS symptoms in mice and opening the door to future human trials.

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in ...

Breast cancer incidence trends differ by age, even among older women, particularly by race and ethnicity and stage at ...

During animal development, cells divide and arrange themselves in a coordinated way, eventually forming the embryo. The cells ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...